Our recent BIND Paper has garnered some attention, including over 1 million views for one article on Twitter.

Our 3rd and final paper of the benzodiazepine survey is the focus of a recent Psychology Today article.

The third and final paper from the benzodiazepine survey — which formerly introduces BIND terminology — is now published.

Fluoroquinolones can cause neuropathy and other side effects, especially in benzodiazepine-affected individuals.

Video of my conversation on Angela Peacock's channel is now available. Please check it out.

A recent article in Forbes Health discusses medication classes commonly prescribed for anxiety. As with so many articles on benzodiazepines and antidepressants, this one includes some valuable information — but it also falls far short when it comes to dependence and withdrawal. In the May 18th Forbes Health article, "Anxiety Medication: Types and Side Effects," contributing author Becca Stanek explores four classes of psychiatric medication. These are selective serotonin reu

A recent article in Pharmacy Times highlights the concern of benzodiazepine use in medical settings, especially with older adults. In a May 11 article by Richard P. Dutton, MD, the author states that "minimizing unnecessary benzodiazepine use has become an important principle for patients and anesthesiologists hoping to have the clearest, quickest emergence from anesthesia, with the lowest risk for delirium or any other cognitive dysfunction." Alternatives for treating anxiet

According to a recently updated article in AARP, antianxiety drugs (benzodiazepines) top the list of memory-robbing medications. Benzodiazepines include drugs such as alprazolam (Xanax), lorazepam (Ativan), diazepam (Valium), clonazepam (Klonopin), and many others. In the article, Dr. Armon B. Neel, Jr. stated that "benzodiazepines dampen activity in key parts of the brain, including those involved with the transfer of events from short-term to long-term memory." He cautioned

I'm hitting the road again...and this time, it's to a national drug conference. Over six months ago, a few of us at the Benzodiazepine Action Work Group applied to present a seminar at the Rx and Illicit Drug Summit in Atlanta, Georgia on April 10-13, 2023. To our pleasant surprise, we were accepted. The title of our presentation is "Benzodiazepine Safety: A Patient-Centered Approach" and it includes information on benzodiazepine prescribing, deprescribing, the patient experi